

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



聯康生物科技集團有限公司*

Uni-Bio Science Group Limited

(incorporated in the Cayman Islands with limited liability)

(stock code: 690)

ANNOUNCEMENT

This announcement is made in accordance to Rule 13.09 of the Listing Rules.

The Board of Directors wishes to update the shareholders on the development and progress, in a chronological order, of the application for resumption of trading of the Company's shares in the Stock Exchange of Hong Kong Limited.

On 1 March 2010, the ICAC executed a search warrant at the Company's premises and seized certain property/documents, including but not limited to accounting records and ledgers, corporate documents, computers, annual reports and financial statements.

On the same day, the ICAC arrested two of the Company's employees; both of them are accounting staff of the Company (one of whom is the Company's then Chief Financial Officer and Company Secretary) and not Directors. Both were subsequently released on bail.

On 8 March 2010, the ICAC arrested the Chairman and executive Director, whom was subsequently released unconditionally.

Except as described above and to the best of the Board's knowledge and belief:

- (i) no other Director and/or employee of the Company has been arrested; and
- (ii) no charges have been laid by the ICAC against the Company, or any of the Company's subsidiaries, Directors and/or employees.

As of the date of this announcement, all bails laid on the above mentioned staff and officer had been released.

During the period from 15 March 2010 to 25 June 2010, one member of the Board of Independent Non-Executive Directors and the Ex-Chief Financial Officer and Company Secretary resigned on their own accords.

* *For identification purposes only*

At the same time, three new Independent Non-Executive Directors and a new Chief Financial Officer and Company Secretary, all of whom are professionals, were appointed to rectify and strengthen the management controls.

On 29 March 2010, the Company received a letter from the Stock Exchange in which the Stock Exchange stated the following resumption conditions for the Company:

- (i) informing the market all material information about the ICAC's investigation that is necessary to appraise the position of the Company and its subsidiaries ("**Group**"), including the implications to the Group's operations, assets and financial position.
- (ii) demonstrating circumstances which suggest that there may be significant deficiencies in the internal control system of the Group and/or concern about management integrity of the Group which will pose a risk to investors no longer exist; and
- (iii) providing a reasonable assurance on (i) and (ii) above through works done by independent non-executive directors of the Company and independent professional parties.

The letter also stated that the Stock Exchange may modify any of the above and/or impose further conditions at its discretion.

On 15 April 2010, certain press articles ("**Articles**") published on various newspapers and journals regarding among other things, the Group's acquisitions of three PRC companies ("**Subject Companies**") during the period from August 2005 to July 2007 and the identity of the controlling shareholder of the Company.

The Board of Directors of the Company had clarified, on its announcement dated 13 May 2010 that to its best knowledge after making reasonable enquiries, (i) the controlling shareholder or single largest shareholder (as the case may be), at the material time was and at present is Automatic Result Limited, which is wholly and beneficially owned by the chairman of the Board and an executive director of the Company; (ii) the Board opined that there exists no invisible controlling shareholder of the Company as mentioned in the Articles; and (iii) the Board confirmed that the sellers of the Subject Companies as mentioned in the Articles are independent third parties. The Board also wishes to declare that it has no knowledge of any additional details about the charge referred to in the Articles.

It also clarified that with references to the published materials in respect of the acquisitions of the Subject Companies, the Board did not note that there were any sign of irregularities or any outstanding queries from any parties or professionals concerned whatsoever. To the best knowledge and according to all the information available to the Company at the respective material times, the Company was dealing with independent third parties in connection with the acquisitions of the Subject Companies.

In response to the Stock Exchange's request, the Company's Board of Independent Non-Executive Directors engaged, in June 2010, different independent professionals valuers and accountants to perform independent review and assessments on the three acquisitions concerned, as well as any consequential effect, financial or otherwise, to the Group.

On 21 January 2011, the Company made a voluntary announcement on the substantial development and achievement of the Company's major research projects. These achievements indicated and substantiated the Company's continual and genuine effort to crystalize its research results by commercialize the outcome and products, and benefits the shareholders as a whole.

On 8 February 2011, the Company announced that the reports of the four independent external business valuers engaged to re-perform valuations of the said three business acquisitions have indicated that the respective acquisition prices in question were in fact advantageous to the Company.

In late December 2011, the Independent Review Report performed by the independent professional accountant was completed and submitted to the Board of Independent Non-Executive Directors, who had discussed, accepted and recommended the same to the Company. On 16 January 2012, the Company submitted the said review report together with the relevant supportive documents and papers to the Stock Exchange pending on their review and comments.

At the date of this announcement, the Company is still in the progress of liaising with the ICAC to seek to obtain further information concerning its investigation and request the return of certain property and documents.

The Company is currently engaged in discussion with the Stock Exchange over the question as to the resumption of trading of shares in the Company. Further announcement will be made by the Company in the event of a material development of the resumption process.

By Order of the Board
Uni-Bio Science Group Limited
TONG Kit Shing
Chairman

Hong Kong, 6 February 2012

As at the date of this announcement, the executive directors of the Company are Mr. TONG Kit Shing and Mr. LIU Guoyao and the independent non-executive Directors are Mr. ZHOU Yaoming, Mr. LIN Jian, Mr. TSAO Hoi Ho, Terry, Mr. LOU Iok Kuong and Mr. LEUNG Ka Chun.